09/04/2024 | Press release | Distributed by Public on 09/04/2024 11:36
Pharmaphorum interviewed Annette Bakker, PhD, CEO of the Children's Tumor Foundation (CTF), who is at the forefront of addressing a critical issue in the pharmaceutical industry: the abandonment of promising drug candidates. Due to the high costs and strategic selectiveness of clinical trials, many potentially life-saving treatments are left undeveloped, languishing on the shelves of large pharmaceutical companies. Annette and CTF are championing a new approach by stepping in to "recycle" these shelved assets, particularly for rare diseases like neurofibromatosis. By leveraging the expertise and resources of non-profits, Bakker is working to revive these overlooked drugs, ensuring they reach the patients who need them most and setting a new standard for drug development in the industry. Click here to read the article.